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Abstract	  
	  	  	  A	   person	   with	   type	   I	   and	   II	   diabetes	   is	   required	   to	   regulate	   and	   monitor	   the	   levels	   of	  glucose	   in	   their	   blood;	   this	   process	   can	   be	   painful	   because	   it	   requires	   the	   person	   to	   get	  pricked	  by	  a	  lancet	  multiple	  times	  a	  day.	  Therefore,	  the	  development	  of	  a	  non-­‐invasive	  and	  pain	   free	   technique	  can	  be	  beneficial	   for	  patients	  with	  diabetes.	  We	  made	  tear	  and	  blood	  glucose	   measurements	   to	   verify	   the	   correlation	   between	   them.	  	   We	   used	   commercially	  available	  glucometers	  and	   tested	   other	   home-­‐built	   alternatives	  glucometers	  with	   varying	  sensitivities	   and	   limits-­‐of-­‐detection	   in	   an	   attempt	   to	   measure	   tear	   glucose	   as	  a	  replacement	  for	  blood	  glucose	  measurements.	  	  
	  	   1	  
Chapter	  1:	  Introduction	  	  	  	  
1.1	  What	  is	  diabetes	  mellitus	  (DM)?	  Diabetes	   mellitus	   (or	   diabetes)	   is	   a	   chronic	   group	   of	   metabolic	   disorders1	  that	  affects	  the	  way	  the	  body	  uses	  digested	  sugar	  for	  energy.	  Diabetes	  is	  categorized	  as	  having	  high	   or	   low	   blood	   sugar	   levels,	   otherwise	   known	   as	   hyperglycemia	   and	   hypoglycemia,	  respectively,	   over	   a	   prolonged	   period	   of	   time.2	  	   During	   the	   digestion	   process,	   the	   body	  breaks	  down	  carbohydrates	   into	  a	  simple	  sugar	  called	  glucose.3	  	  When	  glucose	  enters	  the	  bloodstream,	  the	   increase	   in	  sugar	  concentration	  signals	   the	  pancreas	  to	  produce	   insulin.	  Insulin	  is	  a	  hormone	  that	  helps	  regulate	  the	  uptake	  of	  glucose	  into	  most	  cells	  in	  the	  body.	  Insulin	  also	  helps	  the	  body	  adsorb	  glucose,	  which	  is	  then	  converted	  into	  energy	  needed	  by	  the	   muscles	   and	   tissues	   to	   function	   properly.	   A	   person	   with	   diabetes	   does	   not	   absorb	  glucose	   adequately,	   thus	   when	   glucose	   circulates	   in	   the	   blood,	   it	   can	   cause	   damage	   to	  tissues	  overtime.	  Diabetes	  can	  ultimately	  lead	  to	  detrimental	  damages	  in	  blood	  vessels,	  the	  eyes,	  kidneys,	  and	  nerves.	  It	  may	  also	  increase	  the	  risk	  of	  cardiovascular	  disease	  and	  lower	  limb	   amputations.4	  	   People	   with	   this	   disease	   are	   also	   at	   higher	   risks	   of	   developing	  infections,	   such	   as	   respiratory	   infections,	   urinary	   tract	   infections,	   skin,	   and	   soft	   tissue	  infections.	  Potential	  causes	  of	  diabetes	  include	  the	  pancreas	  not	  producing	  enough	  insulin	  and/or	   the	  cells	   in	   the	  body	  not	   responding	  appropriately	   to	   the	   insulin	  being	  produced.	  Also,	  physiology	  effects,	  such	  as	  obesity	  and	  physical	  inactivity	  are	  strongly	  associated	  with	  the	  development	  of	  type	  2	  diabetes.5	  
	  	   2	  
1.1.1	  Types	  of	  diabetes	  There	  are	  three	  main	  types	  of	  diabetes:	  type	  1,	  type	  2,	  and	  gestational	  diabetes4	  and	  there	   are	   other	   types	   of	   diabetes	   due	   to	   other	   sources,	   such	   as	   monogenic	   diabetes	  syndrome,	   diseases	   of	   the	   exocrine	   pancreas,	   and	   drug	   or	   chemical	   induced	   diabetes.6	  	  Type	  1	  diabetes	   is	   caused	  by	  an	  autoimmune	  response	  where	   the	  body’s	  defense	   system	  attacks	   the	   insulin	   producing	   cells	   in	   the	   pancreas.	   	   This	   type	   of	   diabetes	   results	   from	   a	  cellular-­‐mediated	  autoimmune	  destruction	  that	  is	  often	  mediated	  by	  T-­‐cells,	  of	  the	  insulin-­‐secreting	   cells	   of	   pancreatic	   β-­‐cells.1,7	  Consequently,	   the	   pancreas	   fails	   to	   produce	   the	  insulin	  the	  body	  needs	  to	  regulate	  glucose	  and	  so	  there	  is	  an	  absolute	  deficiency	  of	  insulin.8	  Unfortunately,	   the	   reasons	  behind	   this	  mechanism	  are	   still	   unknown.	  People	  with	   type	  1	  diabetes	   may	   not	   survive	   without	   a	   source	   of	   daily	   insulin	   for	   glucose	   regulation.4	  Susceptibility	  to	  type	  1	  diabetes	  is	  inherited;	  however,	  the	  mode	  of	  inheritance	  is	  complex	  and	  has	  not	  been	  fully	  defined	  yet.1	  Additionally,	  environmental	  factors	  have	  been	  proven	  to	  play	  a	  role	  in	  the	  pathogenesis	  of	  type	  1	  diabetes,	  but	  this	  is	  being	  studied	  further.1	  Type	   2	   diabetes,	   the	   most	   common	   type	   is	   caused	   by	   a	   combination	   of	   bodily	  malfunctions,	   namely,	   insulin	   resistance	   and	   β-­‐cell	   dysfunction.	   These	   are	   pathological	  defects	   in	  patients	  with	  type	  2	  diabetes.1	   	   Insulin	  resistance	  is	  a	  decrease	  in	  the	  ability	  of	  insulin	  to	  act	  on	  the	  peripheral	  tissue.	  The	  β-­‐cell	  dysfunction	  is	  the	  inability	  of	  the	  pancreas	  to	  generate	  the	  necessary	  insulin	  to	  compensate	  for	  insulin	  resistance.	  In	  other	  words,	  type	  2	  diabetes	  develops	  when	  the	  cells	  fail	  to	  respond	  to	  insulin	  properly	  or	  the	  insulin	  amount	  is	  not	  sufficient.	  This	  type	  of	  diabetes	  can	  arise	  from	  genetic	  or	  lifestyle	  factors.	  Gao	  et	  al.	  reported	  that	  type	  2	  diabetes	  is	  mainly	  caused	  by	  a	  decrease	  in	  peripheral	  tissue	  sensitivity	  to	  insulin	  as	  well	  as	  decreased	  insulin	  secretion	  from	  the	  β-­‐cells.	  As	  a	  result	  of	  the	  decline	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in	  sensitivity,	  the	  β-­‐cells	  start	  to	  increase	  insulin	  secretion.	  When	  the	  β-­‐cells	  start	  to	  over	  compensate	   in	   this	   manner,	   it	   leads	   to	   overstraining	   on	   the	   β-­‐cells.	   Overworked	   β-­‐cells	  start	   to	  decrease	   their	   function,	  which	   leads	   to	  a	  subsequent	  decrease	   intolerance,	  which	  impairs	   the	   secretion	   of	   glucagon.	   Glucagon	   is	   a	   hormone	   secreted	   by	   the	   α-­‐cells	   of	   the	  pancreas	   that	   activates	   gluconeogenesis,	   which	   prevents	   hypoglycemia	   when	   no	   food	   is	  being	   digested.	  When	   glucagon	   is	   unable	   to	   achieve	   its	   function,	   the	   glycemic	   state	   of	   a	  patient	  worsens	  and	   leads	   to	  an	  accumulation	  of	  diabetic	  pathology.7	  As	  a	  result	  of	   these	  events,	  glucose	  accumulates	   in	   the	  blood	  at	  high	  concentrations.	  Type	  2	  diabetes	  may	  be	  considered	  the	  “silent	  killer”	  since	  many	  people	  with	  this	  condition	  may	  remain	  unaware	  of	  it	  because	  its	  symptoms	  may	  take	  years	  to	  develop,	  surface,	  and	  even	  be	  recognized.	  Unlike	  people	   with	   type	   1	   diabetes,	   type	   2	   diabetes	   patients	   do	   not	   require	   a	   daily	   dosage	   of	  insulin;	   instead	   their	   condition	   can	   be	   managed	   by	   daily	   physical	   activity,	   physical	  medication,	  and	  a	  healthy	  diet.	  	  Gestational	   diabetes	  mellitus	   is	   defined	   as	   any	   degree	   of	   glucose	   intolerance	   that	  only	   develops	   and	   is	   recognized	   during	   the	   second	   or	   third	   trimester	   of	   pregnancy.9	  Normal	  pregnancy	   is	  associated	  with	  an	   increase	   in	   insulin	  resistance,	  a	  normal	  glycemic	  level	  is	  maintained	  by	  increased	  insulin	  secretion.	  	  Gestational	  diabetes	  develops	  in	  women	  who	  fail	  to	  increase	  insulin	  sufficiently.1	  This	  type	  of	  diabetes	  predisposes	  women	  and	  the	  child	  to	  an	  increased	  risk	  of	  developing	  type	  2	  diabetes	  later	  in	  life.	  Moreover,	  it	  has	  been	  linked	  to	  adverse	  health	  effects	  including	  macrosomia,	  shoulder	  dystocia,	  and	  fetal	  death.10	  	  Because	  of	  the	  health	  risks	  gestational	  diabetes	  bestows	  on	  both	  the	  mother	  and	  the	  child,	  a	  non-­‐invasive,	  virtually	  pain-­‐free	  technology	  to	  measure	  glucose	  would	  greatly	  benefit	  this	  group.	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Figure	  1	  depicts	  three	  possible	  scenarios	  for	  the	  regulation	  of	  glucose.	  In	  a	  normal	  situation	   (Figure	   1	   a),	   the	   pancreas	   creates	   insulin,	   which	   promotes	   the	   absorption	   of	  glucose	  into	  cells	  to	  either	  store	  or	  use	  the	  blood	  glucose	  gained	  from	  food.	  In	  a	  person	  with	  type	  1	  diabetes	   (Figure	  1	  b),	   the	  pancreas	   is	   unable	   to	  produce	   insulin,	   thus	   the	   glucose	  cannot	  enter	  the	  cells,	  which	  results	  in	  glucose	  build	  up	  in	  the	  blood.	  In	  a	  person	  with	  type	  2	  and	  gestational	  diabetes	  (Figure	  1	  c),	  the	  body	  is	  able	  to	  make	  insulin,	  but	  over	  time	  the	  pancreas	  will	  incrementally	  produce	  less	  of	  it.11	  In	  this	  case,	  the	  fat,	  liver,	  and	  muscle	  cells	  are	  unable	  to	  respond	  correctly	  to	  insulin	  and	  therefore,	  glucose	  does	  not	  get	  into	  the	  cells	  to	  be	  stored	  or	  used	  for	  energy.	  
	  
Figure	  1	  Glucose	  pathway	  in	  non-­‐diabetics	  and	  diabetics	  (Adapted	  from	  IDF	  Diabetes	  Atlas	  6th	  edition,	  2013)	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1.1.2	  How	  is	  diabetes	  screened	  and	  diagnosed?	  Diabetes	   is	   screened	   and	   diagnosed	   based	   on	   a	   variety	   of	   tests,	   such	   as	   the	   A1C,	  plasma	   glucose	   test,	   fasting	   plasma	   glucose	   (FPG)	   and	   the	   2-­‐h	   plasma	   glucose	   (2-­‐h	   PG)	  value	  after	  a	  75-­‐g	  oral	  glucose	  tolerance	  test	  (OGTT).1,12,13	  The	  A1C	  test	  also	  known	  as	  the	  hemoglobin	  A1C	  reflects	  a	  person’s	  average	  blood	  glucose	  levels	  for	  the	  past	  two	  to	  three	  months.	  Specifically,	  this	  test	  measures	  the	  percentage	  of	  hemoglobin	  covered	  with	  sugar;	  the	  higher	  the	  percentage,	  the	  greater	  is	  the	  person’s	  risk	  of	  diabetes	  complications.14	  	  An	  A1C	  level	  of	  6.5%	  or	  higher	  indicates	  that	  the	  person	  has	  diabetes.	  Besides	  the	  A1C,	  the	  FPG	  test	  measures	  the	  blood	  glucose	  levels	  when	  the	  person	  has	  fasted	  for	  at	  least	  eight	  hours.	  	  A	  blood	  sugar	  level	  from	  100	  to	  125	  mg/dL	  (5.6	  to	  6.9	  mmol/L)	  is	  considered	  prediabetes,	  a	   level	   of	   126	  mg/dL	   (7.0	  mmol/L)	   or	   higher	  may	   indicate	   diabetes.	   The	   2-­‐h	   PG	   test	   is	  similar	   to	   the	  FPG	   in	   that	   the	  person	  has	   to	   fast	   for	   at	   least	  8	  hours,	  but	   in	  addition,	   the	  person	  has	  to	  drink	  a	  75-­‐grams	  glucose	  drink	  and	  after	  two	  hours,	  another	  blood	  sample	  is	  drawn.	  A	  blood	  sugar	  level	  less	  than	  140	  mg/dL	  (7.8	  mmol/L)	  is	  normal,	  from	  140	  to	  199	  mg/dL	  (7.8	  to	  11.0	  mmol/L)	  is	  considered	  prediabetes,	  and	  levels	  above	  200	  mg/dL	  (11.1	  mmol/L)	  may	  indicate	  diabetes.1,13	  Table	  1	  summarizes	  these	  different	  tests.	  
Table	  1:	  Criteria	  for	  the	  diagnosis	  of	  diabetes12,13	   	  
A1C≥6.5%	  (48	  mmol/mol)	  Performed	  in	  a	  laboratory	  using	  a	  method	  that	  is	  NGSP	  certified	  and	  standardized	  to	  the	  DCCT	  assay	   	  
FRP≥126	  mg/dL	  (7.0	  mmol/L)	  Fasting	  is	  defined	  as	  no	  caloric	  intake	  for	  at	  least	  8	  hours	   	  
2-­‐h	  PG≥200	  mg/dL	  (11.1	  mmol/L)	  during	  an	  OGTT(75-­‐g)	  	  Performed	  after	  fasting	  for	  at	  least	  8	  hours,	  then	  test	  is	  repeated	  after	  	  using	  a	  glucose	  load	  containing	  the	  equivalent	  of	  75	  g	  anhydrous	  glucose	  dissolved	  in	  water	   	  
Random	  plasma	  glucose	  ≥200	  mg/dL	  (11.1	  mmol/L)	  In	  a	  patient	  with	  classic	  symptoms	  of	  hyperglycemia	  or	  hyperglycemic	  crisis	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The	  commonality	  between	  all	  these	  tests	  is	  that	  every	  individual	  with	  diabetes	  must	  have	   their	   blood	   drawn	   and/or	   prick	   their	   fingers	   to	  monitor	   their	   blood	   glucose	   levels	  throughout	  the	  day.	   	  These	  procedures	  are	  painful,	  discomforting,	  and	  disruptive	  to	  one’s	  daily	   life.	   As	   a	   consequence,	  many	  people	  with	   diabetes	   check	   their	   blood	   glucose	   levels	  less	  often	  than	  recommended.	  Other	  complications,	  such	  as	  calluses	  after	  repeated	  pricking	  on	  fingers	  tips	  have	  been	  reported.15	  If	  a	  less	  invasive	  method	  of	  measuring	  glucose	  levels	  were	   offered,	   perhaps	   patient	   compliance	   would	   improve,	   allowing	   for	   a	   better	   glucose	  monitoring,	  and	  lower	  mortality	  rates	  due	  to	  complications	  from	  diabetes.	  	  
1.1.3	  Prevalence	  of	  Diabetes	  Mellitus	  Diabetes	   is	   undeniably	   one	   of	   the	   most	   challenging	   health	   problems	   in	   the	   21st	  century.	   	  In	  recent	  years,	  382	  million	  people	  worldwide	  were	  estimated	  to	  have	  diabetes;	  by	  2035	  this	  is	  predicted	  to	  rise	  to	  592	  million	  people.4	  Currently,	  there	  are	  approximately	  36.8	  million	  people,	  about	  9.6%	  of	  the	  American	  population,	  with	  diabetes,	   in	  addition	  to	  86	  million	  people	  who	  have	  prediabetes.4	  	  Without	  the	  proper	  prevention	  and	  management	  plans,	   this	  epidemic	  will	   continue	   to	   increase	  worldwide.	  Figure	  2	  shows	  a	  map	  with	   the	  distribution	  of	  diabetes	  worldwide	   in	  2013.	  As	  depicted	   in	   the	   figure	   the	  Western	  Pacific	  has	   the	   most	   people	   with	   diabetes	   and	   Africa’s	   population	   has	   the	   least	   people	   with	  diabetes	  within	  the	  regions.	  The	  majority	  of	  people	  with	  diabetes	  live	  in	  economically	  less	  developed	   regions	   of	   the	   world,	   even	   though	   Africa	   has	   the	   lowest	   prevalence,	   it	   is	  estimated	  that	  522,600	  people	  died	  due	  to	  diabetes	  in	  2013.	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According	   to	   the	   IDF	  Diabetes	  Atlas,	  within	   a	   country,	   some	   communities	  may	   be	  more	  vulnerable	  to	  diabetes	  than	  others	  because	  of	  socioeconomic	  disadvantage	  and	  lack	  of	  access	  to	  care.	  According	  to	  Gao	  et	  al.	  a	  survey	  conducted	   in	  the	  United	  States	   in	  2008	  revealed	  that	  the	  rates	  of	  type	  2	  diabetes	  are	  dependent	  on	  ethnicity	  as	  the	  greatest	  rise	  in	  childhood	   diabetes	   was	   largely	   in	   non-­‐white	   ethnic	   groups.	   The	   prevalence	   of	   type	   2	  diabetes	   in	  European,	  African-­‐American,	  and	  American-­‐Indian	  communities	  was	   found	   to	  be	   3,	   15.7,	   and	   49.4	   out	   of	   100,000	   individuals,	   respectively.7	   Studies	   have	   shown	   that	  ethnicity	  may	  play	  a	  role	  in	  contributing	  to	  the	  severe	  impact	  of	  diabetes,	  but	  it	  is	  the	  social	  factors	   that	   form	   the	   basis	   for	   many	   of	   the	   chronic	   health	   problems	   faced	   by	   these	  communities.4	  
Figure	  2	  Number	  of	  people	  with	  diabetes	  by	  regions	  around	  the	  world	  (adapted	  from	  IDF	  Diabetes	  Atlas	  6th	  edition,	  2013)	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There	   is	   limited	   global	   prevalence	   data	   for	   diabetes	   in	   youth.	  With	   the	   increasing	  quantities	  of	  childhood	  obesity	  and	  physical	  inactivity,	  the	  potential	  for	  type	  2	  diabetes	  in	  children	   is	   rapidly	   increasing.	  The	  primary	   treatment	   for	   type	  2	  diabetes	   in	   children	   is	   a	  medication	  called	  metformin.	  Metformin	  decreases	  the	  glucose	  production	  and	  stimulates	  the	   glucose	   acceptance	   in	   peripheral	   tissue.7	   Type	   1	   diabetes	   is	   the	   most	   common	  metabolic	   condition	   in	   childhood.	  This	   type	  of	  diabetes	   requires	   life	   long	   insulin	   therapy	  and	   a	   management	   plan	   that	   consists	   of	   insulin	   use	   and	   blood	   glucose	   monitoring.7	   	   In	  many	   low-­‐income	   families	   access	   to	   insulin	   and	   education	   about	   diabetes	   is	   limited;	  furthermore,	   the	   cost	   of	   treatment	   and	   monitoring	   equipment	   can	   be	   expensive.	  Consequently,	   children	   who	   are	   not	   able	   to	   have	   a	   proper	   management	   plan	   can	   have	  disabilities	   and	  even	  early	  death.	  According	   to	  Gao	  et	  al.	  oral	   insulin	   is	  not	   an	  option	   for	  these	  patients	  because	  of	  gastric	  enzymes	  that	  hinder	  oral	  insulin.	  There	  are	  many	  types	  of	  insulin	   that	   can	  be	   administered	   to	   children	  with	   type	  1	  diabetes,	   they	   all	   have	  different	  functioning	   time,	   but	   they	   have	   a	   similarity:	   the	   method	   of	   insulin	   delivery.	   Insulin	   is	  generally	  injected	  using	  a	  fine	  needle	  and	  a	  syringe	  or	  a	  pen.	  Many	  children	  may	  also	  use	  an	  adjustable	   insulin	  pump.	  A	   tube	   connects	   the	   insulin	   to	   a	   catheter	   that	   is	   inserted	   in	   the	  abdomen,	  which	  delivers	  the	  appropriate	  amount	  of	   insulin.7	  As	  of	  now,	  for	  patients	  with	  type	   1	   diabetes	   insulin	   is	   still	   being	   administered	   in	   an	   invasive	  manner.	  However,	  with	  more	  research,	  the	  method	  for	  measuring	  glucose	  levels	  may	  be	  noninvasive,	  in	  the	  hopes	  of	  alleviating	  these	  patients	  from	  further	  pain	  and	  discomfort.	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1.2	  How	  is	  glucose	  measured	  from	  blood?	  	  As	   a	   way	   to	   regulate	   glucose	   levels,	   diabetics	   need	   to	   continually	   monitor	   their	  glucose.	   A	   blood	   glucose	   test	   measures	   the	   amount	   of	   glucose	   in	   the	   blood.	   Home	  glucometers	  are	  medical	  devices	  that	  allow	  the	  patient	  to	  monitor	  their	  own	  blood	  glucose	  concentration.	  Glucometers	  are	  intended	  to	  measure	  glucose	  levels	  in	  fresh	  capillary	  whole	  blood	  samples	  drawn	  from	  fingertips,	  forearm,	  upper	  arm,	  and	  palm.16	  According	   to	   Tonyushkina	   et	   al.	   Ernie	   Adams	   invented	   the	   first	   glucometer,	  Dextrostix,	   in	   1963.	   The	  Dextrostix	   consisted	   of	   a	   paper	   strip	   that	   develops	   a	   blue	   color	  whose	   intensity	   is	   proportional	   to	   glucose	   concentration	   and	   could	   be	   read	   by	   visually	  comparing	   the	  strip	  color	   to	  a	   color-­‐concentration	  chart.17	  	   In	  1970,	  Anton	  H.	  Clemens	  at	  the	  Ames	  Research	  Division	  in	  Indiana	  first	  developed	  an	  instrument	  to	  self-­‐monitor	  blood	  glucose	   levels	   with	   Dextrostix.	   His	   invention	   used	   a	   dry	   chemistry	   test	   strip	   and	   a	  reflectance	  photometry.18	  
	  
Figure	  3	  Evolution	  of	  glucometers	  (a)	  Reflomat	  (1974),	  (b)	  Reflolux	  (1984)18,	  and	  the	  (c)	  Accu-­‐Chek	  (2014)	  
(a)	   	   	   	   	   (b)	   	   	   	   (c) 
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  In	  1974,	  Boehringer	  Mannheim	  (BM)	  fabricated	  the	  Reflomat	  in	  Figure	  3	  (a),	  a	  reflectance	  meter	   that	   uses	   a	   reagent	   strip	   and	   small	   volumes	   of	   blood.	   Subsequently,	   in	   1984,	   BM	  produced	  the	  Reflolux	  (Accu-­‐Chek),	  which	  used	  improved	  reagent	  strips	  and	  small	  volumes	  of	   blood,	   as	   well	   as	   better	   visual	   quality.18	   	   In	   the	   1990s	   these	   tests	   switched	   from	  colorimetric	  to	  electrochemical	  methods.	  	  A	  modern	  glucometer	  is	  one	  launched	  by	  Rogue	  Diagnostics,	  the	  Accu-­‐Chek	  System,	  which	  requires	  0.6	  microliter	  volume	  samples	  yielding	  5-­‐second	  results	  and	  clear	  visual	  reading	  of	  the	  glucose	  concentration.19	  	  
1.2.1	  How	  do	  glucometers	  work?	  	  Glucose	  meters	  have	   two	   important	  parts:	  an	  enzymatic	  reaction	  and	  a	  detector.17	  Enzymes	  are	  protein	  catalysts,	  which	  accelerate	  specific	  chemical	  reactions;	  they	  are	  highly	  selective	  and	  specific,	  which	  enables	  the	  measurement	  of	  a	  specific	  type	  of	  molecule	  within	  different	   cells. 20 	  The	   enzymatic	   part	   of	   the	   glucometer	   is	   generally	   packaged	   in	   a	  dehydrated	   state	   in	   a	   disposable	   test	   strip.	   When	   blood	   is	   applied	   to	   the	   test	   strip,	   it	  rehydrates	   the	   enzyme,	   glucose	   oxidase	   (GOx).	   GOx	   oxidizes	   β-­‐D-­‐glucose	   almost	  exclusively,	  even	  in	  the	  presence	  of	  α-­‐D-­‐glucose21,	  a	  stereoisomer	  (Figure	  4).	  This	  reaction	  yields	   a	   product	   that	   can	   be	   detected	   either	   optically	   or	   electrochemically.	   Some	  meters	  generate	  hydrogen	  peroxide,	  which	  then	  can	  be	  measured	  electrochemically.	  Others	  have	  an	   intermediary	   that	   can	   react	  with	   a	   dye,	   such	   that	   the	   converted	   dye	   concentration	   is	  proportional	  to	  the	  concentration	  of	  glucose.18 	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α-­‐D-­‐glucose	  	   	   	   	   	   	   	   β-­‐D-­‐glucose	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Figure	  5	  Cross	  section	  of	  key	  part	  of	  a	  glucose	  test	  strip	  (adapted	  from	  diabetes.org)	  
Figure	   5	   displays	   a	   cross	   section	   of	   a	   test	   strip.	   The	   Diabetes	   Forecast	   magazine	  describes	  the	  anatomy	  of	  test	  strips	  in	  the	  following	  way.	  The	  top	  layer	  is	  a	  coating	  made	  up	  of	  an	  adhesive	  material	  to	  protect	  the	  circuit.	  Then	  there	  are	  four	  layers	  that	  make	  up	  the	  sample	  chamber;	  these	  are	  adhesive	  materials	  and	  a	  spacer.	  The	  chamber	  has	  a	  small	  transparent	   window	   that	   gives	   the	   observer	   a	   visual	   indication	   that	   the	   strip	   has	   been	  properly	  loaded	  with	  the	  blood	  sample.	  The	  next	  small,	  yellow	  layer	  is	  where	  the	  chemical	  reaction	   takes	   place.	   The	   enzyme	   oxidizes	   the	   glucose	   and	   transfers	   an	   electron	   to	   a	  mediator,	   which	   then	   passes	   them	   into	   the	   circuit	   via	   an	   electrode.	   In	   the	   meter	   the	  electrons	  are	  measured	  as	  current	  and	  it	  is	  this	  measured	  current	  which	  is	  converted	  into	  a	  concentration	  of	  glucose	  based	  on	  a	  calibration	  curve.23	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1.2.2	  Electrochemical	  Sensors	  	  Electrochemical	   sensors	   are	   the	   industry	   standard	   because	   they	   display	   low	  detection	   limits,	   have	   faster	   response	   times,	   and	   are	   less	   expensive	   than	  other	   detection	  platforms.24	  Electrochemistry	  implies	  that	  there	  is	  a	  transfer	  of	  charge	  from	  an	  electrode	  to	  another	  phase	  (i.e.	  liquid	  to	  solid),	  both	  the	  electrode	  reactions	  and/or	  the	  charge	  transport	  can	  be	  chemically	  controlled	  and	  serve	  as	  the	  basis	  of	  the	  sensing	  process.25	  A	  fundamental	  rule	   that	   applies	   to	   all	   electrochemical	   sensors	   is	   that	   they	   must	   be	   a	   closed	   circuit,	  meaning	   that	   there	   is	   a	   sensor	   electrode	   and	   a	   signal	   return.	   There	   are	   three	   important	  parts	   that	  make	  up	   a	   three-­‐electrode	   electrochemical	   cell:	   (1)	   the	  working	   electrode,	   (2)	  auxiliary	  (counter)	  electrode,	  and	  (3)	  the	  reference	  electrode.	  	  
	  
Figure	  6	  A	  conventional	  three-­‐electrode	  electrochemical	  cell	  	   Figure	  6	  portrays	  a	  typical	  schematic	  of	  a	  three-­‐electrode	  electrochemical	  cell	  setup	  with	  the	  aforementioned	  electrodes.	  Depending	  on	  whether	  the	  electrons	  are	  added	  to	  or	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withdrawn	  from	  the	  sample,	  the	  working	  electrode,	  acts	  as	  either	  an	  anode	  (oxidation)	  or	  a	  cathode	  (reduction).	  For	  the	  working	  electrode	  the	  potential	  with	  respect	  to	  the	  reference	  electrode	   is	   varied	   overtime.	   The	   role	   of	   a	   reference	   electrode	   is	   to	   provide	   a	   stable,	  reversible,	   and	   reproducible	   voltage	   so	   that	   the	   working	   electrode	   potential	   may	   be	  referenced.26	  In	   other	   words,	   it	   establishes	   a	   chemical	   potential	   that	   is	   constant	   against	  other	   potentials,	   which	   can	   be	   measured.	   The	   counter	   electrode	   functions	   as	   a	   cathode	  when	  the	  working	  electrode	  is	  operating	  as	  an	  anode	  and	  vice	  versa,	  it	  conducts	  electrons	  from	  the	  signal	  source	  through	  solution	  to	  the	  working	  electrode.	  Counter	  electrodes	  have	  a	  larger	  surface	  area	  than	  the	  working	  electrode	  to	  ensure	  that	  the	  half-­‐reactions	  occurring	  does	  not	  limit	  the	  process	  occurring	  at	  the	  working	  electrode.	  	  	  
1.2.3	  Chronoamperometry	  	  In	   chronoamperometry	   (aka	   amperometry),	   a	   constant	   potential	   is	   applied	   to	   the	  working	   electrode,	  which	   results	   in	   an	   oxidation	   or	   a	   reduction	   at	   the	   electrode	   surface,	  and	  the	  consequential	  current	  is	  measured	  overtime.	  This	  current	  scales	  linearly	  with	  the	  analyte	   concentration	   at	   low	   concentrations.	   The	   chemical	   reaction	   for	   a	   typical	   glucose	  measurement	  is	  demonstrated	  in	  Reaction	  1.	  	  A	  voltage	  is	  applied	  to	  the	  working	  electrode	  vs.	   a	   reference	   electrode	   and	   the	   resulting	   anodic	   current	   shown	   in	   Reaction	   2	   is	  monitored.	  It	  is	  worth	  noting	  that	  current	  only	  flows	  if	  the	  voltage	  applied	  is	  greater	  than	  the	  decomposition	  voltage.	  The	  deposition	  voltage	  refers	  to	  the	  minimum	  voltage	  required	  between	  the	  cathode	  and	  anode	  for	  electrolysis	  to	  occur.25	  Amperometric	   enzyme	   electrodes	   have	   revolutionized	   the	   development	   of	  biosensors.	  The	  history	  of	  enzyme	  electrodes	  started	  in	  1962	  with	  the	  development	  of	  the	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first	  device	  by	  Clark	  and	  Lyons,	  as	  they	  gave	  the	  first	  description	  of	  the	  biosensor.18	   	  The	  first	  enzymatic	  part	  of	  the	  biosensor	  relied	  on	  a	  thin	  layer	  of	  GOx	  entrapped	  on	  a	  working	  electrode	   via	   a	   semipermeable	   dialysis	  membrane.	   The	  measurements	   are	   based	   on	   the	  monitoring	   the	   oxygen	   consumed	   by	   the	   enzyme-­‐catalyzed	   reaction.27	  The	   reaction	   is	  shown	  in	  Figure	  6.	  	  
	  
	  
Reaction	  1	  Reaction	  in	  coating	  above	  working	  electrode	  	   H2O2	  à	  O2	  +	  2H+	  +	  2e-­‐	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1.2.4	  Mediators	  	  A	   difficulty	   of	   the	   glucose	   monitor	   developed	   by	   Clark	   and	   Lyons	   was	   the	  dependence	   on	   the	   concentration	   of	   O2	   in	   the	   enzyme	   layer.	   The	   way	   to	   reduce	   the	  dependence	  of	  O2	  is	  to	  substitute	  it	  with	  a	  mediator.	  Electrochemical	  measurements	  often	  require	  mediating	  reagents,	  which	  are	  substances	  that	  facilitate	  or	  mediate	  the	  transfers	  of	  electrons.	   Potassium	   ferricyanide	   is	   a	  well-­‐known	  mediator,	   and	   it	   is	   often	  used	   to	   react	  with	  GOx	  since	  it	  facilitates	  the	  transfer	  of	  a	  single	  electron	  from	  glucose	  to	  the	  electrode.	  This	  particular	  mediator	  is	  reduced	  to	  ferrocyanide	  in	  the	  process.	  The	  chemical	  reactions	  on	  the	  electrode	  surface	  are	  depicted	  in	  Reaction	  3.	  The	  glucose	  in	  the	  blood	  sample	  reacts	  with	   the	   GOx	   to	   form	   glucolactone,	   which	   then	   reacts	   with	   ferricyanide	   to	   form	  ferrocyanide.27	  	  The	  electrode	  oxidizes	  the	  ferrocyanide,	  and	  this	  generates	  a	  current	  that	  is	  proportional	  to	  the	  glucose	  concentration.	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1.3	  Other	  approaches	  to	  measuring	  glucose	  concentration	  Due	   to	   the	  growing	  global	   epidemic	  of	  diabetes,	   there	   is	   an	   increased	  demand	   for	  glucose	  sensors	  that	  are	  both	  biocompatible	  and	  have	  increased	  sensing	  capabilities.	  Thus,	  there	   has	   been	   intense	   research	   geared	   towards	   development	   of	   non-­‐invasive	   glucose	  sensors.	  This	  includes	  nonenzymatic	  glucose	  sensors,	  fluorescence,	  and	  prototype	  wireless	  circuit	  biosensors.	  Ahmad	   et	  al.	  developed	   a	   nonenzymatic	   glucose	   biosensor	   based	   on	   copper	   oxide	  (CuO)	  nanoparticles	   inject-­‐printed	  on	  silver	  electrodes.	  CuO	  nanoparticles	  were	  prepared	  as	  ink	  using	  a	  mixture	  of	  solvents.	  Their	  working	  electrode	  was	  based	  on	  a	  Si/Ag	  with	  CuO	  nanoparticles.	   They	   performed	   cyclic	   voltammetry	   measurements	   using	   the	   synthesized	  electrode	   to	   verify	   workability	   on	   human	   serum,	   and	   the	   calculated	   results	   were	   in	  accordance	  with	  the	  known	  concentration	  of	  glucose	  from	  the	  serum.	  This	  is	  an	  innovative	  method	   for	   mass	   production,	   as	   well	   as	   for	   long-­‐term	   analysis	   of	   glucose	   as	   an	  amperometric	  sensor	  for	  blood	  serum.28	  Research	   groups	   are	   also	   working	   on	   fluorescence-­‐based	   glucose	   detection	  methods.	   Yuan	   et	   al.	   developed	   fluorescence	   detection	   techniques	   based	   on	   manganese	  dioxide	   (MnO2)	   nanosheet-­‐modified	   upconversion	   nanoparticles	   (UCNPs)	   for	   fast	   and	  sensitive	  glucose	  detection	   in	  human	  serum.29	  A	  sample	  may	  fluoresce	  based	  on	  the	  H2O2	  mediated	   reduction	   of	   MnO2	   to	   Mn2+,	   which	   leads	   to	   the	   decomposition	   of	   the	   MnO2	  nanosheets.	  Thus,	  because	  glucose	  can	  be	  oxidized	  by	  O2	  in	  the	  presence	  of	  GOx	  to	  produce	  H2O2,	   a	   biosensor	   can	   be	   constructed	   based	   on	   the	   ‘upconversion’	   florescence	   assay	   for	  monitoring	  blood	  glucose.	  Figure	  7	  below	  explains	  this	  concept.	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Figure	  7	  Design	  and	  principle	  for	  H2O2	  and	  glucose	  detection	  using	  a	  MnO2-­‐nanosheet-­‐modified	  UCNP	  nanocomposite	  (acquired	  from	  Applied	  Material	  Interfaces	  2015)	  	  Figure	  7	  illustrates	  that	  MnO2	  nanosheets	  were	  formed	  and	  functionalized	  onto	  the	  UCNPs	   surface.	  MnO2	   quenches	   the	   upconverted	   luminescence;	   this	   effect	   is	   reversed	   by	  adding	  H2O2,	  which	  prompts	   the	  reduction	  of	  MnO2	  to	  Mn2+.	  This	  method	  shows	  promise	  for	  more	  sensitive	  methods	  and	  clinical	  diagnosis	  in	  diabetes.	  Moreover,	   the	   latest	   noninvasive	  way	   to	   detect	   glucose	   has	   been	  made	   by	  Google	  along	  side	  Novastis,	  a	  European	  drug	  company.	  They	  are	  working	  on	  a	  Smart	  Contact	  Lens	  Project,	  which	  uses	  contact	  lenses	  with	  a	  wireless	  chip	  and	  a	  miniaturized	  glucose	  sensor	  embedded	   between	   two	   layers	   of	   soft	   contact	   lens	  material.30	  Figure	   8	   displays	   how	   the	  prototype	  might	   look	   as	   a	   contact	   lens.	   This	   device	   allegedly	  measures	   glucose	   levels	   in	  tears	  although	  the	  mechanism	  of	  how	  this	  might	  work	  is	  still	  unknown	  to	  the	  public.	  This	  device	   is	   still	   in	   the	   prototype	   phase	   and	   various	   clinical	   trials	   and	   FDA	   approval	   are	  required	  before	  it	  is	  commercially	  available.	  This	  device	  might	  be	  difficult	  for	  some	  patients	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to	  use	  because	  not	  everyone	  is	  accustomed	  to	  wearing	  contact	  lens	  and	  people	  may	  even	  be	  opposed	  to	  inserting	  a	  foreign	  object	  in	  their	  eye.	  The	  methodologies	  used	  in	  these	  studies	  are	  very	  intrusive	  for	  the	  patient;	  however,	  the	  method	  presented	  in	  this	  project	  provides	  a	  non-­‐invasive	  approach.	  	  
	  
Figure	  8	  Smart	  Constant	  Lens	  Project	  with	  wireless	  circuit	  	  
1.4	  Measurements	  of	  tear	  glucose	  concentration	  The	   usual	   approach	   to	   measuring	   glucose	   requires	   an	   invasive	   and	   sometimes	  painful	  methodology	  by	  the	  withdrawal	  of	  blood.	  As	  an	  alternative	  to	  blood,	  approaches	  to	  measure	  glucose	   in	  easily	  accessible	   fluids,	  such	  as	  urine,	  saliva,	  and	  tear	   fluid	  have	  been	  investigated,	   as	   they	   have	   great	   potential	   for	   noninvasive	   diagnosis	   and	  management	   of	  diabetes.31	  A	  correlation	  between	  tear	  glucose	  and	  blood	  glucose	  has	  been	  studied,	  but	  the	  results	  are	  inconclusive.	  LeBlanc	  et	  al.	  found	  a	  lack	  of	  consistent	  correlation	  between	  tear	  and	   blood	   glucose	   values.	   However,	  Meyerhoff	   et	   al.	   reported	   a	   correlation	   between	   the	  two.	  Moreover,	  other	  researchers	  have	  reported	  that	  there	  is	  evidence	  of	  correlations,	  but	  more	  studies	  should	  be	  conducted	  to	  determine	  the	  potential	  utility.32	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There	   is	   still	   controversy	   on	   the	   correlation	   between	   the	   concentrations	   of	   tear	  glucose	   in	   normal	   and	   diabetic	   patients.33	  However,	   Baca	   et	   al.	   concluded	   that	   there	   is	  evidence	   indicating	   a	   correlation	   in	   the	   average	   tear	   and	   glucose	   levels	   in	   rabbits,	   but	  further	   characterization	   and	   measurements	   are	   necessary	   from	   human	   studies	   to	  determine	  potential	  utility	  of	   tear	   glucose	  measurements.	   	  Meyerhoff	  et	  al.	   examined	   the	  use	  of	  commercial	  glucometer	  strips	  that	  require	  less	  than	  1	  µL	  to	  measure	  glucose	  in	  tears.	  Many	   research	   groups	   have	   examined	   the	   detection	   methods	   and	   limits	   for	   measuring	  levels	  of	   glucose	   in	   tears	  .34	  In	   the	  1980s,	   it	  was	  discovered	   that	   tear	   glucose	   levels	  were	  significantly	  higher	  in	  diabetic	  patients	  than	  those	  in	  regular	  patients.34	  	  However,	  the	  tear	  glucose	   levels	   are	   30-­‐50	   times	   lower	   than	   the	   blood	   glucose	   levels.	   As	   such,	   Meyerhoff	  describes	   a	   needle-­‐type	   amperometric	   enzyme	   electrode	   for	   glucose	   that	   is	   capable	   of	  measuring	   the	   levels	   of	   glucose	   in	   tear	   fluid	   down	   to	   1.5	   μM	   within	   a	   capillary	   tube	  containing	  approximately	  5	  μL	  of	   tear	   fluid.	  This	  research	  group	  concluded	  that	   in	  rabbit	  models,	  there	  was	  a	  significant	  correlation	  between	  tear	  and	  blood	  glucose	  levels,	  but	  the	  exact	  correlation	  varies	  from	  rabbit	  to	  rabbit.	  The	   blood	   glucose	   concentration	   for	   patients	  without	   diabetes	   ranges	   from	   70	   to	  140	  mg/dL	  (3.9-­‐7.8	  mmol/L)	  before	  meals	  and	  peaks	  about	  200	  mg/dL	  (11.1	  mmol/L)	  for	  up	   to	   two	  hours	   after	   a	  meal.	   Patients	  with	  diabetes	   can	   reach	  a	   range	  greater	   than	  240	  mg/dL	   (13.3	  mmol/L).35	  In	   contrast,	   average	   fasting	   glucose	   concentration	   in	   tears	  were	  previously	  measured	   to	  be	  0.2	  mmol/L	   for	  non-­‐diabetics	   and	  0.92	  mmol/L	   for	  diabetics.	  Table	  2	  displays	  data	  of	  tear	  glucose	  concentrations	  based	  on	  literature	  from	  1980,	  2005,	  2006,	  2007,	  and	  2010,	  thus	  confirming	  that	  there	  is	  glucose	  concentration	  in	  tears.	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Table	  2:	  Comparison	  of	  non-­‐diabetic	  vs.	  diabetic	  glucose	  concentration	  in	  tears	  
Author/	  journal/	  year	   Non-­‐diabetic	   Diabetics	  La	  Baella.	  Journal	  of	  Diabetes	  Science	  and	  Tech,	  2010.36	   0-­‐0.28	  mmol/L	  (5-­‐20	  mg/dL)	   N/A	  Baca,	  J.	  The	  Ocular	  Surface,	  2007.33	  	   0-­‐3.6	  mM	  (65	  mg/dL),	   4.7	  mM	  (84	  mg/dL)	  Lane	   J.D.	   Current	   Eye	   Research,	  2006.39	  	   0.35	  ±	  0.04	  mmol/L	  (6.34	  ±	  0.7	  mg/dL)	   0.16	  ±	  0.03	  mmol/L	  (2.9	  ±	  0.5	  mg/dL)	  LeBlanc	  J.M.	  Intensive	  Care	  Med.,	  2005.37	   7.25	  ±	  5.47	  μmol/L	   N/A	  Sen,	  D.K.	  British	  Journal	  of	  Ophthalmology,	  1980.38	   0.2	  mmol/L	  (3.6	  mg/dL)	   0.92	  mmol/L	  (16.6	  mg/dL)	  	   In	   2014,	   Cha’s	   research	   team	   at	   the	   University	   of	   Michigan	   published	   an	   article	  examining	   commercial	   glucometer	   test	   strips	   for	   the	  measurement	   of	   glucose	   in	   tears.32	  They	  understood	  that	  regular	  measurements	  and	  control	  of	  blood	  glucose	  was	  important	  to	  avoid	   life-­‐threating	  hyper	  and	  hypoglycemic	  events	  and	  side	  effects	   that	  were	  associated	  with	   long-­‐term	   complications.	   Some	   of	   the	   complications	   are:	   retinopathy,	   nephropathy,	  neuropathy,	  macrovascular	  disease,	  and	  amputations.	  For	  optimal	  control	  of	  glucose	  levels	  a	   patients	   must	   check	   their	   glucose	   at	   least	   four	   times	   a	   day.	   However,	   children	   and	  adolescents	  with	  type	  1	  diabetes	  on	  insulin	  therapy	  must	  check	  their	  glucose	  levels	  up	  to	  eight	  times	  a	  day.39	  The	  discomfort	  that	  can	  arise	  from	  monitoring	  glucose	  levels	  so	  many	  times	  a	  day	   limits	  patient	   compliance	   to	  monitor	   and	   regulate	   their	   glucose	   levels.	  Thus,	  with	  this	  in	  mind	  Cha	  et	  al.	  tested	  how	  well	  different	  commercial	  test	  strips	  measured	  the	  concentration	  of	  glucose.	  	  It	  was	  concluded	  that	  ACCU-­‐CHEK	  Aviva	  Plus	  glucometer	  exhibit	  the	   sensitivity	   and	   selectivity	   necessary	   to	   measure	   glucose	   concentration	   in	   tears.	   In	  addition,	  Cha	  suggests	  that	  methods	  for	  measuring	  tear	  glucose	  must	  have	  low	  micromolar	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range	   limit	  of	  quantification	   (LOQ),	  high	  selectivity	  over	   interferences,	   and	  measurement	  potential	  within	  microliter	  sample	  volumes.32	  	  	  
1.5	  Objective	  The	  development	  of	  a	  non-­‐invasive	  and	  pain-­‐free	  technique	   for	  measuring	  glucose	  concentration	  will	  be	  beneficial	  for	  patients	  with	  diabetes.	  	  The	  goal	  of	  this	  project	  is	  to	  find	  a	   noninvasive	   way	   to	   monitor	   their	   glucose	   levels	   without	   the	   discomfort	   and	   painful	  pricking	  of	  fingers.	  	  This	  may	  help	  decrease	  the	  risk	  of	  the	  complications	  that	  may	  surface	  as	   a	   result	   of	  not	  monitoring	  glucose	   levels	   and	   increase	  patient	   compliance.	   	  To	   control	  blood	   glucose	   levels,	   regular	  monitoring	   is	   required.	   	  We	   aim	   to	   use	   tear	   glucose	   as	   an	  alternative	  for	  the	  discussed	  blood	  glucose	  measurements.	  In	  order	  to	  do	  this,	  we	  must	  first	  test	  if	  there	  is	  a	  correlation	  between	  the	  tear	  glucose	  and	  blood	  glucose	  concentrations.	  	  We	  used	  commercially	  available	  glucometers	  to	  test	  blood	  glucose	  concentration	  and	  a	  home-­‐built	   alternative	   biosensor,	   the	   tearometer,	   using	   the	   electrochemical	   technique	   of	  chronoamperometry.	   	   We	   hope	   to	   optimize	   the	   biosensor	   device	   by	   measuring	   the	  sensitivities	  and	  limits-­‐of-­‐detection	  to	  accurately	  measure	  tear	  concentrations.	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Chapter	  2:	  Experimental	  	  	  	  
2.1	  Chronoamperometry	  experiments	  Chronoamperometry	  measurements	  were	  carried	  out	  using	  a	  Potentiostat,	  CHInstruments	  (CHI)	  Model	  604E	  Picoamp	  Booster	  &	  Faraday	  Cage	  and	  the	  CHInstruments	  Electrochemical	  
Analyzer	  (Figure	  9	  a),	  this	  was	  controlled	  by	  a	  computer	  via	  CHInstruments	  software.	   	  All	  measurements	  were	  obtained	  at	  room	  temperature.	  	  	  
2.1.1	  Preparation	  of	  glucose	  The	  1	  M	  glucose	  stock	  solution	  with	  DI	  water	  was	  be	  prepared	  at	   least	  24	  hours	  prior	  to	  performing	   the	   experiments	   and	   stored	   in	   a	   dark	   refrigerator	   at	   4°C	   in	   order	   for	   the	  glucose	  to	  mutarotate40,41	  to	  β-­‐D-­‐glucose.	  	  From	  this	  stock	  solution,	  several	  dilutions	  were	  made	  and	  used:	  100	  mM,	  10	  mM,	  1	  mM,	  and	  0.1	  mM	  of	  glucose.	  	  	  
2.1.2	  Preparation	  of	  phosphate	  buffer	  and	  glucose	  oxidase	  	  A	  10	  mM	  phosphate	  buffer,	  0.1	  M	  NaCl	  stock	  solution	  adjusted	  to	  pH	  7.0	  was	  obtained.	  Glucose	   oxidase	   (GOx)	   from	   Aspergillus	   Niger	   (17,300	   units	   g−1),	   was	   obtained	   from	  Sigma–Aldrich;	  2000	  units	  of	  GOx	  was	  mixed	  with	  100	  μL	  of	  the	  10	  mM	  phosphate	  buffer	  (pH	  7.0)	  and	  stored	  at	  4°C.	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2.1.3	  Preparation	  of	  dialysis	  membrane	  A	   10	   cm	   long	   fragment	   of	   dialysis	   membrane	   (MWCO	   12,000)	   was	   boiled	   in	   a	   1%	  w/v	  sodium	   carbonate	   solution	   for	   10	  minutes	   and	   then	   it	   was	   stored	   in	   0.01	  M	   Tris	   buffer	  containing	   1	   M	   EDTA	   at	   4°C.	   The	   dialysis	   membrane	   was	   soaked	   in	   10	   mM	   phosphate	  buffer	  for	  a	  minimum	  of	  5	  minutes	  before	  using.	  	  
2.1.4	  Polishing	  the	  electrodes	  The	  electrodes	  were	  polished	  with	  a	  CHI	  electrode	  polishing	  kit.	  The	  working	  electrode	  was	  a	  3	  mm	  diameter	  Pt	  electrode;	  it	  was	  rinsed	  with	  DI	  water,	  then	  methanol,	  and	  wiped	  dry.	  Three	   alumina	   grits	   were	   used,	   1	   μm,	   0.5	   μm,	   and	   0.1	   μm,	   sequentially.	   The	   alumina	  suspension	  was	   dispensed	   evenly	   on	   the	   surface	   of	   the	   pad.	   The	  working	   electrode	  was	  placed	   faced	  down	  on	   the	  nylon	  microcloth	  pad,	  and	   the	  electrode	   is	  moved	   in	  a	  circular	  motion	  all	  over	  the	  pad.	  After	  ~1	  minutes,	  the	  electrode	  was	  removed	  and	  rinsed	  with	  DI	  water.	  	  
2.1.5	  Preparation	  of	  electrochemical	  cell	  A	   platinum	   (Pt)	   disk-­‐working	   electrode	   was	   used	   for	   all	   of	   the	   experiments	   performed.	  	  	  Figure	   9(c)	   shows	   the	   surface	  where	   the	   electrochemical	   reaction	   takes	   place.	   A	   pipette	  was	  used	  to	  place	  5	  μL	  of	  GOx	  on	  the	  clean	  surface	  of	  the	  Pt	  working	  electrode.	  A	  2x2	  cm2	  piece	   of	   dialysis	   membrane	   was	   carefully	   placed	   on	   top	   on	   the	   electrode	   surface.	   	   The	  membrane	  was	  fixed	  by	  an	  O-­‐ring	  and	  submerged	  in	  a	  10	  mL	  of	  phosphate	  buffer.	  Figure	  9c	  shows	   the	   surface	   of	   the	   working	   electrode.	   	   The	   platinum	   counter	   electrode	   and	   the	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Ag/AgCl	   reference	   electrode	   were	   also	   submerged	   in	   the	   buffer	   and	   connected	   to	  potentiostat	  for	  analysis	  (Figure	  9b).	  	  
	  	  
Figure	  9	  (a)	  the	  potentionstat.	  (b)	  the	  electrochemical	  setup	  with	  working	  electrode	  (green),	  reference	  electrode	  (white)	  and	  counter	  electrode	  (red).	  (c)	  Surface	  of	  the	  working	  electrode	  where	  the	  enzyme	  catalyze	  chemical	  reaction	  takes	  place	  	  For	  experiments	  that	  used	  larger	  volumes	  of	  buffer	  (e.g.	  10	  mL,	  5	  mL)	  a	  shot-­‐glass	  shaped	  container	  is	  used.	  For	  experiments	  that	  use	  small	  volumes	  of	  buffer	  (e.g.	  200	  μL)	  a	  coned-­‐shaped	  shot	  glass	  is	  used	  as	  shown	  in	  Figure	  9.	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2.1.6	  Chronoamperometry	  parameters	  	  The	  chronoamperometry	  parameters	  used	  are	  shown	  below.	  	  
Table	  3:	  Parameters	   	  
Initial	  Voltage	  (V)	   0	  
High	  Voltage	  (V)	   0.652	  
Low	  Voltage	  (V)	   0.65	  
Initial	  Step	  Polarity	   Positive	  
Number	  of	  Steps	   1	  
Pulse	  Width	  (sec)	   120	  
Sample	  Interval	  (sec)	   1	  
Quiet	  Time	  (sec)	   2	  
Sensitivity	  (A/V)	   1	  e-­‐005	  
	  
2.2	  Collection	  of	  blood	  and	  tears	  	  The	  procedure	  for	  the	  measurement	  and	  collection	  of	  blood	  and	  tears	  was	  approved	  by	  the	  Institutional	  Review	  Board.	  The	  verbal	  consent	  to	  participate	  in	  the	  experiment,	  the	  consent	  to	  withdraw	  and	  measure	  blood,	  the	  preliminary	  questions,	  and	  advertising	  poster	  can	  be	  found	  in	  the	  supplemental	  information.	  	  
2.2.1	  Procedure	  for	  performing	  blood	  glucose	  tests	  Step	  1:	  The	  subject	  washes	  their	  hands	  with	  soap	  and	  water.	  Step	  2:	  The	  meter	  is	  turned	  on.	  After	  3	  seconds,	  the	  test	  strip	  is	  inserted	  into	  the	  glucometer	  in	  the	  direction	  of	  the	  arrows.	  Step	  3:	  On	  the	  meter	  screen,	  a	  test	  strip	  and	  a	  flashing	  blood	  drop	  appear	  on	  the	  display.	  Step	  4:	  The	  lancet	  device	  is	  loaded	  with	  the	  lancet	  and	  ready	  for	  use.	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Step	  5:	  The	  subject	  uses	  the	  lancet	  device,	  aims	  it	  at	  their	  finger	  and	  gets	  a	  blood	  drop.	  Step	  6:	  The	  blood	  drop	  is	  placed	  to	  the	  front	  edge	  of	  the	  window	  on	  the	  test	  strip.	  Step	  7:	  The	  blood	  glucose	  concentration	  is	  displayed	  on	  the	  screen.	  Step	  8:	  The	  test	  strip	  is	  taken	  out	  of	  the	  meter	  and	  the	  lancet	  from	  the	  lacing	  device	  and	  properly	  disposed.	  Step	  9:	  The	  person	  must	  wash	  their	  hands	  again	  and	  place	  a	  band-­‐aid	  over	  affected	  area.	  	  
2.2.2	  Procedure	  for	  obtaining	  tears	  To	   induce	  tears,	   the	  participant	  used	  a	  commercially	  available	   lachrymator,	  Kryolan	  Tear	  Stick,	  which	  contains	  menthol.	  The	  Kryolan	  was	  rubbed	  15	  millimeters	  under	  the	  eye,	  the	  warmth	  from	  the	  skin	  released	  menthol	  vapors,	  which	  induces	  tear	  production.	  The	  tears	  (~200	   μL)	   were	   collected	   in	   a	   micro-­‐centrifuge	   tube	   after	   the	   blood	   glucose	   level	   was	  measured.	  
	  (Left)	  A	  participant	  applying	  Kryolan	  tear	  stick	  under	  the	  eye	  to	  induce	  tears.	  (Right)	  Participant	  collecting	  their	  tears	  in	  micro-­‐centrifuge	  tube.	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2.2.3	  Chronoamperometry	  measurements	  For	  a	  typical	  calibration	  curve	  a	  shot-­‐glass	  containing	  10	  mL	  of	  phosphate	  buffer	  equipped	  with	   a	   micro	   stir	   bar	   was	   used.	   The	   potentiostat	   was	   set	   up	   with	   the	   appropriate	  parameters	   and	   after	   the	   electrochemical	   cell	   was	   ready	   for	   use.	   	   The	   enzyme	   was	  conditioned	  by	  applying	  a	  constant	  voltage	  (0.65	  V)	  to	  the	  working	  electrode	  in	  a	  buffered	  solution	  for	  15	  minutes.	  	  This	  data	  was	  saved	  as	  buffer	  with	  [0]	  glucose.	  Next,	  10	  μL	  of	  the	  1	  M	  (100	  mM,	  10	  mM,	  1	  mM,	  or	  0.1	  mM)	  glucose	  stock	  solution	  was	  added	  to	  the	  shot-­‐glass	  and	   stirred	   for	   exactly	   2	  minutes.	  Next,	   the	   shot-­‐glass	  was	   placed	   back	   into	   the	   Faraday	  cage	   and	   the	   amperometry	   data	   was	   measured	   for	   2	   minutes.	   Subsequently	   10	   μL	   of	  glucose	  was	  added	  again,	  and	  these	  last	  steps	  were	  repeated	  several	  times.	  	  	  For	  a	  glucose	  calibration	  curve	  with	  human	  tears	  a	  cone-­‐shaped	  shot	  glass	  was	  used.	  The	  potentiostat	   was	   set	   up	   with	   the	   appropriate	   parameters	   and	   subsequently	   the	  electrochemical	  cell	  was	  set	  up,	   the	  enzyme	  was	  conditioned	   in	   the	   tears	   for	  10	  minutes.	  The	  data	  collected	  was	  saved	  as	  tear	  buffer	  with	  [0]	  glucose.	  Next,	  10	  μL	  of	  1	  mM	  glucose	  solution	   is	  added	   to	   the	  shot-­‐glass	  and	  mixed	  with	  a	  pipette.	  The	  amperometry	  data	  was	  measured	  and	  saved;	   the	  current	  at	   the	  end	  of	   the	  2	  minutes	  was	  collected	  and	  graphed.	  Then,	  10	  μL	  of	  glucose	  was	  added	  again,	  and	  these	  last	  steps	  were	  repeated	  several	  times	  until	  a	  calibration	  curve	  was	  obtained.	  	  
2.2.4	  Calibration	  curve	  for	  precision	  and	  limit	  of	  detection	  To	  measure	  the	  precision	  and	  limit	  of	  detection	  of	  the	  tearometer	  5	  mL	  of	  phosphate	  buffer	  was	  used	   in	  a	  shot	  glass.	  A	  250	  μL	  aliquot	  of	   the	  100	  mM	  concentration	  glucose	  solution	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was	  added	  to	  the	  buffer	  and	  stirred	  for	  2	  minutes,	  after	  which	  the	  current	  was	  monitored	  and	  recorded.	  	  Next,	  20	  μL	  of	  1M	  glucose	  solution	  were	  added	  and	  stirred	  for	  two	  minutes,	  then	  the	  current	  was	  recorded.	  This	  was	  done	  4	  more	  times,	  until	  a	  calibration	  curve	  was	  obtained.	  This	  experiment	  was	  repeated	  five	  times.	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Chapter	  3:	  Results	  and	  Discussion	  	  	  	  
3.1	  Optimizing	  the	  biosensor	  	   In	   experimental	   design	   we	   aim	   to	   find	   the	   conditions	   to	   optimize	   the	   biosensor	  performance.	   Before	   we	   use	   the	   tearometer,	   for	   tear	   measurements	   we	   tested	   different	  parameters	   to	  ensure	   the	  system’s	   ideal	  performance.	  The	  rate	  of	   the	  enzymatic	  reaction	  can	   be	   varied	   by	   changing	   the	   enzyme	   concentration	   substrate	   concentration	   or	   the	  reaction	   temperature. 42 	  	   One	   of	   the	   parameters	   we	   sought	   to	   optimize	   was	   the	  concentration	  of	  GOx,	  which	  is	  at	  the	  heart	  of	  the	  biosensor.	  43	  	  Initially	  we	  used	  1000	  units	  of	  GOx	  and	  performed	  several	  measurements.	  Figure	  10	  shows	  the	  curve	  obtained	  from	  a	  10mM	   glucose	   solution.	   The	   trend-­‐line	   acquired	   from	   the	   graph	   does	   not	   fit	   all	   of	   the	  points.	  	  The	  first	  40	  μL	  added	  do	  not	  seem	  to	  change	  the	  signal,	  but	  after	  60	  μL	  the	  points	  seem	   to	   fit	   the	   trend-­‐line,	  which	   had	   an	  R2	   value	   of	   0.96.	   	  We	  wanted	   detect	   very	   small	  concentrations	   of	   glucose,	   thus	   we	   tried	   2000	   units	   of	   GOx	   instead	   of	   the	   1000	   units.	  	  Figure	  11	  demonstrates	  a	  10	  mM	  glucose	  calibration	  curve	  using	  2000	  units	  of	  GOx.	   	  We	  were	  able	  to	  clearly	  see	  a	  difference	  in	  signal	  from	  the	  first	  addition	  of	  20	  μL	  of	  glucose	  and	  the	  R2	  value	  was	  0.99.	  	  Thereafter	  we	  used	  2000	  units	  of	  GOx.	  	  This	  larger	  concentration	  of	  GOx	   results	   in	   faster	   reaction	   rates	   and	   enhances	   the	   production	   of	   hydrogen	   peroxide.	  Thus,	   for	   optimal	   conditions	   of	   the	   biosensor	   every	  measurement	   performed	   used	   2000	  units	  of	  GOx.	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Figure	  10	  [10	  mM]	  glucose	  calibration	  curve	  in	  aliquots	  of	  20	  μL	  in	  10	  mL	  phosphate	  buffer	  	  
	  
Figure	  11	  [10	  mM]	  glucose	  calibration	  curve	  using	  2000	  units	  of	  GOx	  by	  adding	  20	  μL	  aliquots	  in	  10	  mL	  phosphate	  buffer	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3.2	  Precision	  	   The	   ACCU-­‐CHEK	   Aviva	   Plus	   System	   was	   used	   to	   measure	   blood	   glucose	  concentration	   in	   human	   subjects.	   	   We	   also	   attempted	   to	   measure	   tear	   glucose	  concentration	  with	  the	  glucometer	  device	  since	  Meyerhoff	  et	  al.	  suggested	  that	  this	  would	  be	   the	  best	  glucometer	   for	   samples	  with	   low	  concentration	  such	  as	   tears.	  However,	  after	  several	   trials,	  we	  found	  that	   this	  device	  could	  not	  measure	  tears;	  on	  the	  display	  screen	   it	  read	  LO’	   indicating	   that	   the	  concentration	  was	   too	   low	  to	  be	  detected	  by	   the	  glucometer.	  Thus,	  we	  wanted	  to	  find	  the	  detection	  limit	  of	  the	  device	  so	  we	  ran	  trials	  of	  known	  glucose	  concentrations	  and	  found	  that	  the	  glucometer	  could	  only	  measure	  down	  to	  1	  mM	  glucose	  solutions,	   when	   one	   tries	   to	   measure	   0.1	   mM	   glucose,	   the	   concentration	   is	   too	   low	   to	  measure.	  Therefore,	  the	  limit	  of	  detection	  of	  the	  glucometer	  is	  between	  1	  mM	  and	  0.1	  mM,	  which	  is	  in	  agreement	  with	  the	  manufacturer’s	  specification	  of	  20	  mg/dL	  (1.11	  mM).	  	  In	  order	  to	  measure	  the	  precision	  of	  the	  glucometer	  several	  glucose	  measurements	  were	  taken	  on	  a	  1	  mM	  glucose	  sample.	  	  The	  same	  sample	  solution	  was	  measured	  ten	  times	  and	  the	  following	  readings	  were	  obtained:	  236,	  256,	  258,	  270,	  282,	  287,	  290,	  294,	  299,	  and	  300	  mg/dL.	  The	  average	  measurement	  and	  standard	  deviation	  were	  calculated	  to	  be	  277	  ±	  21	  mg/dL	   (15.4	  mmol/L)	   in	   the	   timespan	   of	   5	  minutes.	  We	   found	   a	   7%	   error	   with	   the	  glucometer.	  	  This	  percentage	  may	  not	  seem	  significant,	  but	  this	  difference	  may	  be	  essential	  to	  a	  patient	  with	  diabetes.	  	  The	  range	  of	  values	  may	  be	  due	  to	  strip-­‐to-­‐strip	  variation,	  and	  large	  difference	  in	  the	  average	  value	  and	  the	  expected	  value	  is	  likely	  due	  to	  matrix	  effects.	  	  The	  matrix	  of	  our	   standard	  was	  DI	  water	  whereas	   the	   strips	   are	   calibrated	   to	   test	  blood	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samples,	  which	  accounts	  for	  the	  increasing	  difference	  in	  the	  measurements	  between	  whole	  blood	  and	  glucose	  solutions.17	  Measuring	  glucose	  in	  tears	  is	  difficult	  for	  two	  reasons:	  i)	  we	  are	  only	  able	  to	  collect	  small	  volumes	  of	  tears	  (200-­‐250	  μL)	  and	  ii)	  the	  glucose	  concentration	  is	  significantly	  lower	  in	   tears	   (0.92	   mmol/L)	   than	   blood	   (~1	   mmol/L).	   	   To	   overcome	   the	   first	   problem	   we	  gradually	  decreased	  the	  volume	  of	  the	  buffer	  we	  use	  to	  make	  measurements.	   	  To	  be	  sure	  the	   tearometer	   could	   deal	  with	   the	   second	   problem	  we	  measured	   the	   precision,	   limit	   of	  detection,	  and	  sensitivity	  of	  the	  tearometer	  to	  investigate	  the	  feasibility	  for	  the	  detection	  of	  glucose	  concentrations	  in	  tears.	  	  To	  evaluate	  the	  precision	  of	  the	  tearometer	  we	  measured	  the	  concentration	  of	  a	  100	  mM	  glucose	  sample	  several	  times.	  	  We	  used	  either	  10	  or	  5	  mL	  of	  buffer	  and	  added	  250	  μL	  of	  the	  glucose	  concentration	  that	  we	  wanted	  to	  measure.	  	  After	  measuring	  a	  baseline	  current,	  we	  performed	  standard	  addition	  by	  adding	  20	  μL	  of	  1	  M	  glucose	  solution.	  The	  current	  was	  measured	  at	  2	  minutes	  after	  every	  addition	  and	  then	  graphed	  to	  create	  a	  calibration	  curve.	  This	  experiment	  was	  repeated	  four	  more	  times	  to	  compare	  the	  calculated	  concentration	  of	  the	  250	  μL	  of	  100	  mM	  glucose	  solution.	  	  A	  total	  of	  five	  measurements	  were	  performed	  and	  the	  following	  concentrations	  were	  calculated:	  152,	  97,	  135,	  152,	  and	  91	  mM.	  The	  average	  measurement	  and	  standard	  deviation	  were	  computed	  to	  be	  125	  ±	  29	  mM.	  	  The	  theoretical	  glucose	  concentration	  was	  100	  mM,	  but	  the	  measured	  value	  was	  125	  mM.	  	  The	  tearometer	  had	  a	  25%	  error	  in	  these	  measurements.	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3.3	  Limit	  of	  detection	  	  	   As	  a	  means	  to	  measure	  the	  limit	  of	  detection	  of	  the	  tearometer	  we	  added	  a	  known	  concentration	   of	   glucose	   solution	   into	   a	   phosphate	   buffer	   solution	   (10	  mL	  or	   5	  mL)	   and	  examined	   the	  current	  as	   it	   responded	   to	  each	  new	  volume	  of	  glucose	  added.	   	  We	  started	  with	   high	   concentrations	   of	   glucose	   solutions	   such	   as	   1	   M,	   100	   mM,	   and	   10	   mM.	   The	  standard	  addition	  calibration	  curves	  for	  the	  aforementioned	  concentrations	  are	  linear	  with	  R2	   values	   of	   0.99.	   The	  10	  mM	  glucose	   concentration	   standard	   addition	   graph,	   Figure	   11,	  shows	  a	  trend-­‐line	  that	  fits	  most	  of	  the	  points	  very	  well.	  	  For	  this	  experiment	  we	  added	  20	  μL	  of	  10	  mM	  glucose	  solutions	  to	  a	  10	  mL	  phosphate	  buffer,	  thus	  diluting	  the	  small	  aliquot	  of	   glucose	   solution	   to	   the	   buffer	   and	   obtaining	   a	   signal	   that	   followed	   the	   trendline.	   This	  signal	   indicates	   that	   the	   tearometer	   can	  measure	   a	   change	   in	   concentration	   of	   20	   μM	  of	  glucose	  solution.	  Next,	  we	  examined	  1	  mM	  of	  glucose	  solution	  in	  5	  mL	  of	  phosphate	  buffer.	  	  Figure	   12	   demonstrates	   that	   the	   linearity	   of	   the	   standard	   addition	   diminishes;	   this	   is	  confirmed	  by	  the	  R2	  value	  of	  0.97.	  However,	  we	  are	  able	  to	  detect	  a	  lower	  concentration	  of	  changes	  in	  glucose	  at	  4	  μM	  as	  it	  is	  diluted	  in	  the	  5	  mL	  buffer.	  	  
	  
Figure	  12	  [1	  mM]	  glucose	  calibration	  curve	  in	  aliquots	  on	  20	  μL	  in	  5	  mL	  phosphate	  buffer	  
y = -0.37x - 33.57 
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Figure	  13	  [0.1	  mM]	  glucose	  calibration	  curve	  in	  aliquots	  on	  20	  μL	  in	  500	  μL	  phosphate	  buffer	  
	  Lastly,	   to	  continue	   testing	   the	   limits	  of	  detection	  we	  used	  a	  0.1	  mM	  glucose	  solution	   in	  a	  500	  μL	  buffer.	  As	  we	  decrease	  the	  glucose	  concentration	  more	  discrepancies	  are	  seen	  in	  the	  graph’s	  linear	  fit.	  	  This	  is	  confirmed	  by	  the	  R2	  value	  of	  0.92	  in	  Figure	  13.	  	  Based	  on	  these	  graphs	  we	  conclude	  that	  the	  limit	  of	  detection	  is	  approximately	  20	  μM.	   	  When	  we	   analyze	   Figure	   10,	   the	   [10	  mM]	   calibration	   curve,	   we	   see	   that	  when	   the	  concentration	  of	  the	  solution	  is	  ~20	  μM	  the	  points	  fit	  the	  trend-­‐line	  almost	  perfectly.	  The	  same	  is	  true	  in	  the	  Figure	  11.	  	  When	  concentrations	  lower	  than	  20	  μM	  were	  measured	  the	  data	  did	  not	  fit	  a	  line	  well	  and	  so	  we	  do	  not	  have	  confidence	  in	  these	  measurements.	  	  At	  20	  μM	   we	   are	   able	   to	   easily	   discriminate	   between	   the	   concentration	   obtained	   from	   the	  measurement	   and	   the	   blank	   sample	   and	   we	   should	   be	   able	   to	   measure	   the	   glucose	  concentration	   in	   tears	   since	   according	   to	   literature	   it	   is	   in	   the	   200	   uM	   range	   (Table	   2),	  which	  is	  approximately	  10	  times	  higher	  than	  our	  current	  detection	  limit.	  
y = -0.91x - 30.79 
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In	  contrast	  to	  the	  limit	  of	  detection	  where	  we	  try	  to	  measure	  low	  levels	  of	  glucose,	  the	  sensitivity	  of	  the	  tearometer	  can	  be	  analyzed	  by	  the	  difference	  in	  signal	  when	  a	  small	  volume	  of	  glucose	  is	  added	  to	  the	  solution.	  	  Thus,	  according	  to	  the	  1	  mM	  calibration	  curve	  (Figure	   12),	   the	   tearometer	   has	   a	   sensitivity	   of	   0.34	   uM/nA,	  which	   enabled	   us	   to	   detect	  changes	  in	  glucose	  concentration	  of	  4	  μM	  when	  the	  standard	  was	  added.	  	  
3.4	  Measuring	  glucose	  concentration	  in	  tears	  	  	   We	   next	   proceeded	   to	   measure	   the	   glucose	   concentration	   in	   human	   tears	   with	  confidence	  that	  the	  tearometer	  would	  be	  able	  to	  detect	  the	  low	  concentrations	  of	  glucose.	  Instead	  of	  our	  usual	  5	  mL	  of	  phosphate	  buffer	  to	  which	  we	  would	  normally	  add	  a	  standard	  glucose	  solution,	  we	  used	  the	  tears	  themselves	  for	  the	  baseline	  measurements	  and	  added	  aliquots	   of	   1	  mM	   glucose	   solution	   for	   the	   calibration	   curve.	   	  When	   the	   tear	   sample	  was	  collected,	   we	   also	   measured	   the	   blood	   glucose	   concentration	   of	   the	   same	   individual	   in	  order	  to	  test	  if	  there	  was	  a	  correlation	  between	  the	  glucose	  levels.	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Figure	  14	  Measurement	  of	  tear	  glucose	  levels	  via	  standard	  addition	  when	  blood	  glucose	  concentration	  was	  91	  mg/dL	  	  In	   order	   to	   calculate	   the	   glucose	   concentration	   in	   the	   tear	  we	   use	   the	   standard	   addition	  equation:	  	   𝑋 !𝑆 ! + 𝑋 ! = 𝐼!𝐼!!!      𝑒𝑞. 1 	  In	  standard	  additions	  a	  sample	  with	  unknown	  initial	  concentration	  of	  analyte,	  [X]i	  ,	  gives	  a	  signal	  intensity	  IX.	  	  Then	  a	  known	  concentration	  of	  standard,	  S,	  is	  added	  to	  an	  aliquot	  of	  the	  sample	  and	  a	  signal,	   IS+X,	   is	  observed	  for	  the	  second	  addition.	  As	  expected	  the	  addition	  of	  the	   standard	   to	   the	   unknown	   changes	   the	   concentration	   of	   the	   original	   analyte	   both	  because	  of	  the	  additional	  analyte	  and	  because	  of	  dilution.	  The	  diluted	  concentration	  of	  the	  analyte	  is	  [X]f	  	  and	  the	  concentration	  of	  the	  standard	  in	  the	  final	  solution	  is	  [S]f.	  	  The	  signal	  is	  directly	  proportional	  to	  analyte	  concentration,	  which	  gives	  equation	  1.	  Equations	  2	  and	  3	  show	  the	  dilution	  factors,	  which	  relate	  the	  final	  concentration	  to	  initial	  concentration.44	  
y = -153.92x - 54.35 
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𝑋 ! = 𝑋 ! 𝑉!𝑉    𝑒𝑞. 2 	  
𝑆 ! = 𝑆 ! 𝑉!𝑉    𝑒𝑞. 3 	  𝑒𝑞. 1  𝑖𝑠  𝑟𝑒𝑎𝑟𝑟𝑎𝑛𝑔𝑒𝑑:	  
𝐼!!!   𝑋 ! = 𝐼!   𝑆 ! + 𝑋 ! 	  
𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑢𝑡𝑒  𝑒𝑞. 2  𝑎𝑛𝑑  3  𝑖𝑛𝑡𝑜  𝑒𝑞. 1  	  
𝐼!!!   𝑋 ! = 𝐼!    𝑆 ! 𝑉!𝑉 + 𝑋 ! 𝑉!𝑉 	  
  𝐼!!! 𝑋 !𝑋 ! = 𝐼! 𝑆 !
𝑉!𝑉𝑋 ! + 𝐼! 𝑋 !
𝑉!𝑉𝑋 !   	  
𝐼!!!   = 𝐼![𝑋]! 𝑆 ! 𝑉!𝑉 + 𝐼! 𝑉!𝑉   	  
𝐼!!!𝑉𝑉!   = 𝐼![𝑋]! 𝑆 ! 𝑉!𝑉 𝑉𝑉! + 𝐼! 𝑉!𝑉 𝑉𝑉! 	  	   Thus	  we	  obtain	  the	  successive	  standard	  addition	  to	  one	  solution	  equation:	  	                                       𝐼!!! !!! = 𝐼! + !!! ! 𝑆 ! !!!! 	  	  	  	  	  	  (eq.4)	  	  	  	  	  	  	  	  function	  for	  y-­‐axis	   function	  for	  x-­‐axis	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Equation	  4	  now	  resembles	  that	  of	  a	  linear	  equation,	  y	  =	  mx	  +	  b,	  where	  the	  Y-­‐axis	  is  𝐼!!! !!! ,	  
and	  the	  X-­‐axis	  is	   𝑆 ! !!!! 	  and	  the	  X-­‐intercept	  is	  [X]i.	  Thus,	  we	  used	  the	  standard	  addition	  equation	  4	  to	  calculate	  the	  unknown	  glucose	  concentration,	  [X]i,	  of	  the	  tear	  from	  the	  graph.	  	  The	  trendline	  equation	  was	  used	  to	  find	  the	  x-­‐intercept	  when	  y=0.	  Hence,	  we	  find	  that	  for	  this	   tear	   sample	   in	   Figure	   13,	   the	   concentration	   is	   0.353	   mM.	   The	   calculation	   is	   the	  following:	  
For	  successive	  standard	  additions	  to	  one	  solution:	  𝐼!!! 𝑉!𝑉 = 𝐼! + 𝐼!𝑋 ! 𝑆 ! 𝑉!𝑉! 	  𝑦 = −153.92𝑥 − 54.35  𝑊ℎ𝑒𝑛  𝑦 = 0  54.35 = 153.92𝑥  0.353 = 𝑥	  Hence,	   when	   the	   blood	   glucose	   level	   of	   the	   person	  was	   91	  mg/dL	   (5.05	  mM)	   their	   tear	  glucose	   concentration	   was	   0.353	   mM.	   This	   measurement	   is	   in	   agreement	   with	   the	  literature’s	  suggested	  order	  of	  magnitude	  for	  tear	  glucose	  concentration.	  	  
3.5	  Correlation	  between	  Blood	  and	  Tear	  Glucose	  Levels	  	   	  	   The	  pearson	  product-­‐moment	  correlation	  coefficient	  (PPMCC)	  is	  a	  measure	  of	  the	  linear	  association	  between	  two	  variables.	  The	  two	  variables	  are	  treated	  equally,	  thus,	  either	  can	  be	   the	  dependent	  or	   independent	  variable.	   	   In	  short,	  a	  PPMCC	  attempts	   to	  draw	  a	   line	  of	  best	  fit	  through	  the	  data	  points	  of	  the	  two	  variables.	  	  A	  Pearson	  coefficient,	  r,	  indicates	  how	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well	  the	  data	  points	  fit	  the	  trend-­‐line.45	  	  The	  strength	  of	  association	  is	  based	  on	  the	  Pearson	  correlation	   coefficient.	   	   The	   stronger	   the	   correlation	   between	   two	   variables,	   the	   closer	   r	  will	  be	  to	  +1	  or	  -­‐1	  depending	  if	  it	  is	  a	  positive	  and	  negative	  relationship,	  respectively.	  The	  closer	  r	   is	   to	  0,	   the	  greater	  the	  distinction	  around	  the	  best-­‐fit	   line.	   	  A	  value	  of	  0	   indicates	  that	  there	  is	  no	  correlation	  between	  the	  two	  variables.	  The	  Pearson’s	  correlation	  makes	  the	  following	  assumption	  about	  the	  variables:	  
• The	  variables	  are	  either	  interval	  or	  ratio	  measurements	  
• The	  variables	  are	  approximately	  normally	  distributed	  
• There	  is	  a	  linear	  relationship	  between	  the	  variables	  
• Outliers	  have	  either	  been	  removed	  or	  minimized	  
• There	  is	  homoscedasticity	  (a	  sequence	  of	  random	  variables)	  of	  the	  data	  	   The	   graph	   in	   Figure	   15	   is	   that	   of	   tear	   glucose	   concentration	   vs.	   blood	   glucose	  concentration.	  Eleven	   trials	  were	  performed	   to	  determine	   the	   tear	  glucose	   concentration	  after	   measuring	   blood	   glucose	   levels.	   	   The	   graphed	   R2	   value	   is	   0.00072.	   Pearson’s	  coefficient,	  r,	  can	  be	  obtained	  by	  finding	  the	  square	  root	  of	  R2,	  and	  the	  calculated	  r	  is	  0.027.	  	  This	  value	   is	  very	  close	   to	  0	  and	   therefore	   indicates	   that	   there	   is	  no	  correlation	  between	  blood	  and	  tear	  glucose	  levels.	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Figure	  15	  Pearson’s	  correlation	  coefficient,	  defines	  the	  association	  between	  two	  variables.	  The	  r	  value	  suggests	  that	  there	  is	  no	  association	  between	  tear	  glucose	  and	  blood	  glucose	  levels.	  	   	  
3.6	  Sources	  of	  error	  	   There	   are	   multiples	   sources	   of	   error	   for	   this	   investigation.	   Only	   eleven	   human	  subjects	  were	  used	  to	  compare	  the	  blood	  and	  tear	  glucose	  concentration.	  A	  greater	  amount	  of	  subjects	  would	  give	  the	  results	  more	  validity	  by	  reducing	  the	  effects	  of	  error.	  	  One	  of	  the	  main	  problems	  arose	  from	  the	  collection	  of	  tears.	  Although	  some	  subjects’	  tears	  were	  easily	  induced,	   for	   others	   the	   Kryolan	   tear	   stick	   had	   no	   effect	   and	   the	   sample	   took	   longer	   to	  obtain.	   Some	   tear	   samples	  were	   analyzed	   immediately,	  while	   others	  were	   analyzed	  ~30	  minutes	   after	   they	  were	   collected.	   The	   time	   between	   transport	   and	  when	   the	   sample	   is	  analyzed	   may	   be	   a	   cause	   for	   the	   discrepancies	   observed.	   In	   addition,	   we	   did	   not	   use	   a	  buffer	   for	   the	   standard	   additions	  when	  determining	   tear	   glucose	   concentrations.	   Instead	  
y	  =	  6.0456x	  +	  105.89	  
R²	  =	  0.00072	  
r=	  0.027	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we	   used	  ~200	   μL	   of	   tears	   and	   added	   20	   μL	   of	   1	  mM	   glucose	   solution,	   which	  may	   have	  minimized	  the	  matrix	  effects	  on	  the	  signal	  acquired,	  but	  may	  have	  perturb	  the	  tear	  matrix.	  Moreover,	  each	  tearometer	  is	  slightly	  different	  from	  one	  another	  despite	  our	  best	  efforts	  in	  trying	   to	   prepare	   them	   the	   same	   way,	   which	   could	   be	   problematic	   when	   comparing	  different	  tears	  samples.	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Chapter	  4:	  Conclusion	  	  	  	   The	   rapidly	   increasing	   population	   and	   style	   of	   living	   have	   created	   a	   need	   for	   the	  development	   of	   biosensors	   for	   detecting	   and	   monitoring	   diseases	   with	   promptness,	  accuracy,	  and	  convenience.	  	  Epidemical	  diseases	  such	  as	  diabetes	  can	  constrain	  the	  way	  of	  life	  of	  an	   individual.	  As	  such,	  helping	  diabetic	  patients	  manage	  their	  disease	  by	  providing	  minimally	  invasive	  measurements	  of	  blood	  glucose	  levels	  is	  important.	  This	  thesis	  aimed	  to	  develop	  a	  non-­‐invasive	  and	  pain	  free	  technique	  for	  patients	  with	  diabetes	  to	  measure	  their	  glucose	  levels.	  We	  report	  the	  ability	  to	  measure	  glucose	  concentration	  in	  human	  tears	  with	  a	   homebuilt	   biosensor,	   the	   tearometer.	   We	   optimized	   the	   biosensor	   device	   to	   reliably	  measure	   glucose	   concentrations	   in	   tears.	   	   The	   tearometer	   has	   a	   limit	   of	   detection	   of	  approximately	  20	  μM,	  which	  is	  below	  the	  report	  tear	  concentrations,	  and	  a	  sensitivity	  of	  ~4	  μM.	   	   This	   device	   has	   a	   precision	   of	   25%	   error.	   	   With	   the	   tearometer,	   we	   were	   able	   to	  successfully	   measure	   the	   glucose	   concentration	   in	   tears,	   but	   we	   were	   unable	   to	   find	   a	  correlation	  between	  tear	  and	  blood	  glucose	  levels.	  This	  limits	  the	  clinical	  utility	  of	  the	  non-­‐invasive	  method	  presented	  in	  this	  investigation	  of	  using	  tears	  as	  an	  alternative	  for	  blood	  in	  glucose	  monitoring	  technique	  for	  diabetes.	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Chapter	  5:	  Supplemental	  Information	  (IRB)	  
	  
5.1	  Consent	  for	  participating	  in	  the	  experiment	  
Generally, a person with type I diabetes is required to regulate and monitor the levels of glucose 
in the blood daily, by pricking their fingers, or else they will not survive. A person going through 
insulin therapy is required to monitor their glucose levels several times a day. This process can 
be painful because it requires the person to get pricked by a lancet or even a needle daily. 
Therefore, the development of a non-invasive and pain free technique can be beneficial for 
patients with diabetes. To solve this problem we want to make tear glucose measurements and 
inspect if there is correlation between blood glucose and tear glucose. If the study confirms that 
there is a correlation, then diabetics will no longer have to endure the daily pains of pricking 
their finger, instead the will just have to provide a tear, which can easily and non-invasively be 
provided. The participant will only have to participate one time. 
 
The blood sample will be compared to the participants’ tear samples using electrochemical 
measurements to see if there is a correlation with the concentration of glucose in the samples. 
Participants will be asked to donate a few drops of blood from the capillaries of their fingers, 
which can be safely collected by them pricking themselves with a lancet, which is usually used at 
home by diabetic patients.  The droplets of blood will be placed on a strip that goes into a 
glucometer.  I will then collect tears from the same participants by using a commercially 
available lachrymator, Kryolan Tear Stick. The Kryolan will be rubbed 15 millimeters under the 
eye, the warmth from the skin will release menthol vapors, which will rise to the eyes and cause 
tears to come out. Then the samples will be collected on a strip and the glucose concentration 
will be measured. The lancet may hurt. There is a small risk of bruising. You will not be paid for 
taking the time to donate a blood sample. You will not be charged for the blood sample. 
Some risks that the participant might experience are emotional or slight physical discomfort. 
Benefits include the satisfaction from contributing to scientific knowledge and candy will be 
provided. 
If you decide not to participate at any moment, it will not affect your job standing, class standing, 
grades, status on an athletic team, or our friendship. 
 
You can always talk to the study investigator about any questions or concerns you have about 
this study.  Contact the study investigator(s) Ayda Gonzalez at (347) 337-6103 and by email 
ag0981@bard.edu. If you have any questions about your rights as a participant in a research 
project or for more information on how to proceed should you believe that you have been injured 
as a result of your participation in this study you should contact the study investigator. 
 
Participants will be recruited on a volunteer basis.  A flyer will be posted in the RKC building 
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5.2	  Verbal	  Consent	  
Donation of Blood Sample for Laboratory Research 
 Consent to Participate  
 
Study Title: Correlation Between Blood Glucose and Tear Glucose Levels 
Study Investigator: Ayda Gonzalez (student) and Christopher LaFratta (Advisor) 
 
Study Purpose 
In this study, the researcher, Ayda Gonzalez will be measuring blood glucose levels and tear 
glucose level with a commercially available glucometer. About 30 people will give blood 
samples for this research. More than 347 million people worldwide have diabetes and this 
number only keeps increasing. A person with type I diabetes is required to regulate and monitor 
the levels of glucose in the blood daily, or else they will not survive. A person going through 
insulin therapy is required to monitor their glucose levels up to 8 times a day. This process can 
be painful because it requires the person to get pricked by a lancet or even a needle daily. 
Therefore, the development of a non-invasive and pain free technique can be beneficial for 
patients with diabetes. To solve this problem we want to make tear glucose measurements and 
inspect if there is correlation between blood glucose and tear glucose. If the study confirms that 
there is a correlation, then diabetics will no longer have to endure the daily pains of pricking 
their finger, instead the will just have to provide a tear, which can easily and non-invasively be 
provided.  
 
You are being invited to participate in this blood and tear sample donation study.  This study is 
being conducted by Ayda Gonzalez, under the supervision of Dr. Christopher LaFratta. 
 
Donation of blood for research is voluntary and you should not be placed under any pressures to 
do so.  You do not have to agree to give a blood sample nor need to explain why you should 
choose not to donate.  Any personal information provided by you in connection with the 
donation will be held in confidence.  Before the experiment is done there will be preliminary 
questions, these questions will be confidential, but if any of the answers are no, the participant 
will not participate in the study. 
 
For reasons of safety, you should NOT donate/volunteer and are excluded from this study 
if: 
 
Ø You know, or think that you might be infected with hepatitis B or hepatitis C. 
Ø You know, or think that you might be infected with HIV – the AIDs virus 
Ø You have a sexual partner who is infected with hepatitis or HIV 
Ø You are unwell at the moment 
Ø You are anemic or receiving treatment for anemia or iron deficiency 
Ø You are, or may be, pregnant 
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Questions before study: 
The only question that will be asked is if the patient is a diabetic? 
Are you a hemophiliac? 
 
What will happen if you take part in this study? 
If you agree to be in this study, you will go to lab 131 and give a blood sample, about 10 drops of 
blood.  You will be seated and blood will be drawn by providing you with a lancet and you will 
prick your index finger.  One small vial of blood will be taken. This will take about five minutes. 
In addition, we will also be collecting your tears, by providing the participant with Kryolan Tear 
Stick, a commercially available lachrymator. The Kryolan will be rubbed 15 millimeters under 
the eye, the warmth from the skin will release menthol vapors, which will rise to the eyes and 
cause tears to come out. The tears will be collected and measure on the glucometer instrument. 
 
Are there risks? 
The lancet will hurt. There is a risk of bruising. 
 
Are there benefits? 
There is no benefit to you. The blood will be used only for laboratory research. 
 
Can I say “No”? 
Yes, you do not have to donate a blood sample for this study.  If you decide not to donate, it will 
not affect your job standing, class standing, grades, status on an athletic team, or our friendship.   
 
Taking part is voluntary: Taking part in this study is completely voluntary. You may skip any 
questions that you do not want to answer. If you decide not to take part or to skip some of the 
questions, it will not affect your current or future relationship with the researchers. If you decide 
to take part, you are free to withdraw at anytime. 
 
Will my personal/medical information be kept confidential? 
We will do our best to protect the information we collect from you and/or your medical record.  
Information which identifies you will be kept secure and restricted.  However, your personal 
information may be given out if required by law.  If information from this research is published 
or presented at scientific meetings, your name and other identifiers will not be used.  Information 
which identifies you will be destroyed when this research is complete. The following 
organizations may look at information about you in your medical and research records: 
Institutional Biosafety committee. 
 
Are there any costs or payments? 
You will NOT be paid for taking the time to donate a blood sample. You will NOT be charged 
for the blood sample. 
 
You may be requested to provide your name and date of birth.  This information will be 
disclosed one time to either Bard College for purposes of appreciating you for 
participation in this study.  
 
 
	  	   47	  
Who can answer my questions about the study? 
You can talk to the study investigator about any questions or concerns you have about this study.  
Contact the study investigator(s) Ayda Gonzalez at (347) 337-6103. 
If you have any questions about your rights as a participant in a research project or for more 
information on how to proceed should you believe that you have been injured as a result of your 
participation in this study you should contact the study investigator. 
 
 
CONSENT TO PARTICIPATE 
 
Statement of consent: I have read the above information, and have received answers to any 
questions I asked. I consent to take part in the study. I have been given copies of this consent 
form to keep. 
 
If you wish to be in this study, please sign below. 
 
________________________________________________ 
Participant's Signature and Today’s Date 
 
________________________________________________ 
Participant’s Name (Printed) 
 
________________________________________________ 
Participant’s Date of Birth 
 
________________________________________________ 
Person Obtaining Consent Signature and Date 
 
       
Person Obtaining Consent Printed 
 
Name of Principal Investigator: Ayda Gonzalez 
Address: 30 Campus Rd Annandale-On-Hudson, NY, 12504  
Telephone Number: (347) 337-6103 
 
Name of Faculty Sponsor: Christopher LaFratta 
Address: 30 Campus Rd Annandale-On-Hudson, NY, 12504 
Telephone Number: (845) 752-2353 
 
If you have questions: The researcher conducting this study is Ayda Gonzalez under the 
supervision of Dr. Christopher LaFratta. Please ask any question you have now. If you have 
questions later, you may contact Ayda Gonzalez at ag0981@bard.edu or at (347) 337-6103. If 
you have any questions or concerns regarding this study, you may contact the Institutional 
Review Board (IRB) at irb@bard.edu or access their website at http://www.bard.edu/irb/.   
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5.3	  Questions	  for	  participant	  before	  the	  experiment	  
Preliminary	  Questions:	  The	  answers	  to	  these	  questions	  will	  be	  confidential.	  Please	  read	  the	  questions	  carefully	  and	  check	  yes	  or	  no	  in	  the	  appropriate	  box.	  These	  questions	  will	  determine	  if	  you	  are	  eligible	  to	  participate	  in	  this	  study.	  	  	  
Full-­‐Length	  Volunteer	  History	  Questionnaire	  (Answer	  yes	  or	  no)	   YES	   NO	  
Are	  you…	   	   	  1.	  Feeling	  healthy	  and	  well	  today?	  	   	   	  2.	  Currently	  taking	  an	  antibiotic?	  	   	   	  3.	  Currently	  taking	  any	  other	  medication	  for	  an	  infection?	  	   	   	  4.	  Have	  you	  taken	  aspirin	  or	  anything	  that	  has	  aspirin	  in	  it?	  	   	   	  
In	  the	  past	  6	  weeks	   	   	  5.	  Female	  donors:	  Have	  you	  been	  pregnant	  or	  are	  you	  pregnant	  now?	  	   	   	  
In	  the	  past	  8	  weeks	  have	  you	   	   	  6.	  Donated	  blood,	  platelets,	  or	  plasma?	  	   	   	  7.	  Had	  any	  vaccinations	  or	  other	  shots?	  	   	   	  8.	  Had	  contact	  with	  someone	  who	  had	  a	  smallpox	  vaccination?	     
In	  the	  past	  12	  months	  have	  you	   	   	  9.	  Had	  a	  blood	  transfusion?	  	   	   	  10.	  Come	  into	  contact	  with	  someone	  else’s	  blood?	  	   	   	  11.	  Had	  an	  accidental	  needle-­‐stick?	  	   	   	  
12. Had a tattoo?    
Have you EVER…   
13. Had a positive test for the HIV/AIDS virus?    
14. Had a bleeding condition or a blood disease?    	  	   	  
	  	   49	  
5.4	  Poster	  for	  advertisement	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